Antitumor activity of magainin analogues against human lung cancer cell lines.

Magainin 1 and magainin 2, originally isolated from African clawed frog Xenopus laevis skin, inhibit the growth of bacteria and fungi. Synthetic magainin A (MAG A) and magainin G (MAG G) are more potent against bacteria and protozoa. In order to determine the antitumor activity of these analogues, we have tested these two analogues against six small cell lung cancer (SCLC) cell lines NCI-H82, NCI-H526, NCI-H678, NCI-H735, NCI-H841, and NCI-H889, which were known to differ by more than 10-fold in their sensitivity to different chemotherapeutic agents, and four normal human fibroblast cell lines. Semiautomated 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays of the six SCLC cell lines revealed average concentrations producing 50% inhibition (IC50) values of 2.6 microM (range, 0.49-9.30 microM) for cisplatin, 2.5 microM (range, 0.39-6.00 microM) for etoposide, and 138.8 nM (range, 55.0-450.0 nM) for doxorubicin. The average IC50 of MAG A was 8.64 microM (range, 6.23-11.7 microM) and that of MAG G was 8.82 microM (range, 4.44-12.5 microM) against the SCLC cell lines. Despite a 10-fold difference in sensitivity to standard chemotherapeutic agents, the IC50 of MAG A and MAG G differs by less than 3-fold. The average IC50 against four normal human fibroblast cell lines was 21.1 microM (range, 12.7-25.6 microM) for MAG A and 29.2 microM (range, 21.3-34.8 microM) for MAG G. Combined exposure to the IC50 concentration of MAG A or MAG G plus IC50 of etoposide or cisplatin decreased the percentage of surviving SCLC cells to 29.0% (range, 26.1-31.7%). MAG A or MAG G had an additive effect when used with standard chemotherapeutic agents. These data suggest that MAG A and MAG G have in vitro antitumor activity against SCLC cell lines.

[1]  J. Barker,et al.  Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Herweijer,et al.  Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.

[3]  C. Zierdt,et al.  Magainin analogs effective against pathogenic protozoa , 1990, Antimicrobial Agents and Chemotherapy.

[4]  A. M. van der Bliek,et al.  Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. , 1990, Cancer research.

[5]  R. Makuch,et al.  Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Zasloff,et al.  Magainins: a new family of membrane-active host defense peptides. , 1990, Biochemical pharmacology.

[7]  M. Zasloff,et al.  Peptides from frog skin. , 1990, Annual review of biochemistry.

[8]  H V Westerhoff,et al.  Magainins and the disruption of membrane-linked free-energy transduction. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Westerhoff,et al.  Magainin 2 amide and analogues Antimicrobial activity, membrane depolarization and susceptibility to proteolysis , 1989, FEBS letters.

[10]  S. Steinberg,et al.  Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). , 1989, Cancer research.

[11]  Hao‐Chia Chen,et al.  Synthetic magainin analogues with improved antimicrobial activity , 1988, FEBS letters.

[12]  L. Case,et al.  Improvement of long-term survival in extensive small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Minna,et al.  Chemosensitivity testing of human lung cancer cell lines using the MTT assay. , 1988, British Journal of Cancer.

[14]  M Zasloff,et al.  Antimicrobial properties of peptides from Xenopus granular gland secretions , 1988, FEBS letters.

[15]  M. Zasloff,et al.  Antimicrobial activity of synthetic magainin peptides and several analogues. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Klastersky,et al.  Therapy of small cell lung cancer: anything new? , 1988, European journal of cancer & clinical oncology.

[17]  M. Zasloff,et al.  Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Minna,et al.  Lung cancer: scalpels, beams, drugs, and probes. , 1986, The New England journal of medicine.

[19]  P. Andersen,et al.  Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Minna,et al.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. , 1985, Cancer research.

[21]  J. Minna,et al.  Growth of human small cell (oat cell) carcinoma of the lung in serum-free growth factor-supplemented medium. , 1980, Cancer research.